Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H

Journal of Medicinal Chemistry

Volumn 59, Issue 10, 2016, Pages 5051-5062

  Kankanala, Jayakanth ^a   Kirby, Karen A ^b   Liu, Feng ^a   Miller, Lena ^c   Nagy, Eva ^c   Wilson, Daniel J ^a   Parniak, Michael A ^c   Sarafianos, Stefan G ^b   Wang, Zhengqiang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; ENDONUCLEASE; METAL ION; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRIDONE DERIVATIVE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; 3-(HYDROXY(PYRIDIN-2-YL)METHYL)-1-METHYL-3-(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)CYCLOBUTANOL; CYCLOBUTANE DERIVATIVE; PYRIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; BIOCHEMICAL ANALYSIS; CHELATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EC50; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; X RAY CRYSTALLOGRAPHY; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HIV REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84971671274     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00465     Document Type: Article

References (48)

1. UNAIDS: AIDS information. http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/.
2. Yeni, P. Update on HAART in HIV J. Hepatol. 2006, 44, S100-103 10.1016/j.jhep.2005.11.021
3. Tramontano, E.; Di Santo, R. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development Curr. Med. Chem. 2010, 17, 2837-2853 10.2174/092986710792065045
4. Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak, M. A.; Hughes, S. H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition J. Mol. Biol. 2009, 385, 693-713 10.1016/j.jmb.2008.10.071
5. Cihlar, T.; Ray, A. S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine Antiviral Res. 2010, 85, 39-58 10.1016/j.antiviral.2009.09.014
6. de Bethune, M. P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res. 2010, 85, 75-90 10.1016/j.antiviral.2009.09.008
7. HIV drugs in development. http://www.thebody.com/index/treat/newdrugs.html (accessed 2016).
8. Parniak, M. A. Unpublishd data.
9. Cao, L.; Song, W.; De Clercq, E.; Zhan, P.; Liu, X. Recent progress in the research of small molecule HIV-1 RNase H inhibitors Curr. Med. Chem. 2014, 21, 1956-1967 10.2174/0929867321666140120121158
10. Klumpp, K.; Hang, J. Q.; Rajendran, S.; Yang, Y. L.; Derosier, A.; In, P. W. K.; Overton, H.; Parkes, K. E. B.; Cammack, N.; Martin, J. A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors Nucleic Acids Res. 2003, 31, 6852-6859 10.1093/nar/gkg881
11. Himmel, D. M.; Maegley, K. A.; Pauly, T. A.; Bauman, J. D.; Das, K.; Dharia, C.; Clark, A. D., Jr.; Ryan, K.; Hickey, M. J.; Love, R. A.; Hughes, S. H.; Bergqvist, S.; Arnold, E. Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site Structure 2009, 17, 1625-1635 10.1016/j.str.2009.09.016
12. Himmel, D. M.; Myshakina, N. S.; Ilina, T.; Van Ry, A.; Ho, W. C.; Parniak, M. A.; Arnold, E. Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs J. Mol. Biol. 2014, 426, 2617-2631 10.1016/j.jmb.2014.05.006
13. Shaw-Reid, C. A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D. B.; Carroll, S. S.; Embrey, M.; Wai, J. S.; Miller, M. D.; Cole, J. L.; Hazuda, D. J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid J. Biol. Chem. 2003, 278, 2777-2780 10.1074/jbc.C200621200
14. Kirschberg, T. A.; Balakrishnan, M.; Squires, N. H.; Barnes, T.; Brendza, K. M.; Chen, X.; Eisenberg, E. J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J. K.; Wang, M.; Watkins, W. J.; Lansdon, E. B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information J. Med. Chem. 2009, 52, 5781-5784 10.1021/jm900597q
15. Williams, P. D.; Staas, D. D.; Venkatraman, S.; Loughran, H. M.; Ruzek, R. D.; Booth, T. M.; Lyle, T. A.; Wai, J. S.; Vacca, J. P.; Feuston, B. P.; Ecto, L. T.; Flynn, J. A.; DiStefano, D. J.; Hazuda, D. J.; Bahnck, C. M.; Himmelberger, A. L.; Dornadula, G.; Hrin, R. C.; Stillmock, K. A.; Witmer, M. V.; Miller, M. D.; Grobler, J. A. Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold Bioorg. Med. Chem. Lett. 2010, 20, 6754-6757 10.1016/j.bmcl.2010.08.135
16. Beilhartz, G. L.; Ngure, M.; Johns, B. A.; Deanda, F.; Gerondelis, P.; Gotte, M. Inhibition of the ribonuclease H activity of HIV-1 reverse transcriptase by GSK5750 correlates with slow enzyme-inhibitor dissociation J. Biol. Chem. 2014, 289, 16270-16277 10.1074/jbc.M114.569707
17. Nowotny, M. Retroviral integrase superfamily: the structural perspective EMBO Rep. 2009, 10, 144-151 10.1038/embor.2008.256
18. Fujishita, T.; Mikamiyama, M.; Kawai, M.; Akiyama, T. Substituted 3-hydroxy-4-pyridone derivative. WO2010110231, 2010.
19. Johns, B. A.; Kawasuji, T.; Weatherhead, J. G.; Taishi, T.; Temelkoff, D. P.; Yoshida, H.; Akiyama, T.; Taoda, Y.; Murai, H.; Kiyama, R.; Fuji, M.; Tanimoto, N.; Jeffrey, J.; Foster, S. A.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Johnson, M. N.; Garvey, E. P.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744) J. Med. Chem. 2013, 56, 5901-5916 10.1021/jm400645w
20. Vernekar, S. K. V.; Liu, Z.; Nagy, E.; Miller, L.; Kirby, K. A.; Wilson, D. J.; Kankanala, J.; Sarafianos, S. G.; Parniak, M. A.; Wang, Z. Q. Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities J. Med. Chem. 2015, 58, 651-664 10.1021/jm501132s
21. Parniak, M. A.; Min, K. L.; Budihas, S. R.; Le Grice, S. F.; Beutler, J. A. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity Anal. Biochem. 2003, 322, 33-39 10.1016/j.ab.2003.06.001
22. Beilhartz, G. L.; Wendeler, M.; Baichoo, N.; Rausch, J.; Le Grice, S.; Gotte, M. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition J. Mol. Biol. 2009, 388, 462-474 10.1016/j.jmb.2009.03.025
23. Sirivolu, V. R.; Vernekar, S. K. V.; Ilina, T.; Myshakina, N. S.; Parniak, M. A.; Wang, Z. Q. Clicking 3 ′-azidothymidine into novel potent inhibitors of human immunodeficiency virus J. Med. Chem. 2013, 56, 8765-8780 10.1021/jm401232v
24. Small-Molecule Drug Discovery Suite 2014-3: Glide, version 6.4; Schrödinger, LLC: New York, 2014.
25. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 10.1021/jm051256o
26. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance Science 1998, 282, 1669-1675 10.1126/science.282.5394.1669
27. Sarafianos, S. G.; Das, K.; Tantillo, C.; Clark, A. D., Jr.; Ding, J.; Whitcomb, J. M.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA EMBO J. 2001, 20, 1449-1461 10.1093/emboj/20.6.1449
28. Su, H.-P.; Yan, Y.; Prasad, G. S.; Smith, R. F.; Daniels, C. L.; Abeywickrema, P. D.; Reid, J. C.; Loughran, H. M.; Kornienko, M.; Sharma, S.; Grobler, J. A.; Xu, B.; Sardana, V.; Allison, T. J.; Williams, P. D.; Darke, P. L.; Hazuda, D. J.; Munshi, S. Structural Basis for the Inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors J. Virol. 2010, 84, 7625-7633 10.1128/JVI.00353-10
29. Lansdon, E. B.; Liu, Q.; Leavitt, S. A.; Balakrishnan, M.; Perry, J. K.; Lancaster-Moyer, C.; Kutty, N.; Liu, X.; Squires, N. H.; Watkins, W. J.; Kirschberg, T. A. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors Antimicrob. Agents Chemother. 2011, 55, 2905-2915 10.1128/AAC.01594-10
30. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse-transcriptase from the human-immunodeficiency-virus Type-1 Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 1222-1226 10.1073/pnas.92.4.1222
31. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D.; Hughes, S. H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 angstrom resolution: implications of conformational changes for polymerization and inhibition mechanisms Structure 1996, 4, 853-860 10.1016/S0969-2126(96)00091-3
32. Sarafianos, S. G.; Das, K.; Clark, A. D., Jr.; Ding, J.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 10027-10032 10.1073/pnas.96.18.10027
33. Hsiou, Y.; Ding, J. P.; Das, K.; Clark, A. D.; Boyer, P. L.; Lewi, P.; Janssen, P. A. J.; Kleim, J. P.; Rosner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance J. Mol. Biol. 2001, 309, 437-445 10.1006/jmbi.2001.4648
34. Tu, X. Y.; Das, K.; Han, Q. W.; Bauman, J. D.; Clark, A. D.; Hou, X. R.; Frenkel, Y. V.; Gaffney, B. L.; Jones, R. A.; Boyer, P. L.; Hughes, S. H.; Sarafianos, S. G.; Arnold, E. Structural basis of HIV-1 resistance to AZT by excision Nat. Struct. Mol. Biol. 2010, 17, 1202-1209 10.1038/nsmb.1908
35. PyMOL: www.pymol.org (accessed 2016).
36. Fletcher, R. S.; Holleschak, G.; Nagy, E.; Arion, D.; Borkow, G.; Gu, Z.; Wainberg, M. A.; Parniak, M. A. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase Protein Expression Purif. 1996, 7, 27-32 10.1006/prep.1996.0004
37. Gong, Q.; Menon, L.; Ilina, T.; Miller, L. G.; Ahn, J.; Parniak, M. A.; Ishima, R. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor Chem. Biol. Drug Des. 2011, 77, 39-47 10.1111/j.1747-0285.2010.01052.x
38. Kirby, K. A.; Marchand, B.; Ong, Y. T.; Ndongwe, T. P.; Hachiya, A.; Michailidis, E.; Leslie, M. D.; Sietsema, D. V.; Fetterly, T. L.; Dorst, C. A.; Singh, K.; Wang, Z.; Parniak, M. A.; Sarafianos, S. G. Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase Antimicrob. Agents Chemother. 2012, 56, 2048-2061 10.1128/AAC.06000-11
39. Wang, Z.; Bennett, E. M.; Wilson, D. J.; Salomon, C.; Vince, R. Rationally designed dual inhibitors of HIV reverse transcriptase and integrase J. Med. Chem. 2007, 50, 3416-3419 10.1021/jm070512p
40. Abram, M. E.; Parniak, M. A. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain J. Virol. 2005, 79, 11952-11961 10.1128/JVI.79.18.11952-11961.2005
41. Bauman, J. D.; Das, K.; Ho, W. C.; Baweja, M.; Himmel, D. M.; Clark, A. D.; Oren, D. A.; Boyer, P. L.; Hughes, S. H.; Shatkin, A. J.; Arnold, E. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design Nucleic Acids Res. 2008, 36, 5083-5092 10.1093/nar/gkn464
42. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 125-132 10.1107/S0907444909047337
43. Matthews, B. W. Determination of Protein Molecular-weight, hydration, and packing from crystal density Methods Enzymol. 1985, 114, 176-187 10.1016/0076-6879(85)14018-8
44. Mccoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674 10.1107/S0021889807021206
45. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954 10.1107/S0907444902016657
46. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 10.1107/S0907444904019158
47. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255
48. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B.; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 2007, 35, W375-W383 10.1093/nar/gkm216